Related Experiment Video
Updated: Oct 10, 2026

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
Published on: April 28, 2023
Ruzinurad: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Ruzinurad (®) is an orally administered, small-molecule, selective inhibitor of urate transporter 1 (URAT1) that is being developed by the Jiangsu Hengrui Pharmaceuticals Co. for the treatment of hyperuricaemia associated with gout. By inhibiting the transport function of URAT1, ruzinurad suppresses uric acid reabsorption, thereby promoting uric acid excretion, leading to a reduction in serum uric acid levels. In May 2026, the National Medical Products Administration in China approved ruzinurad tablets for patients with hyperuricaemia associated with gout. This article summarises the milestones in the development of ruzinurad leading to this first approval for patients with hyperuricaemia associated with gout.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinically Relevant Drug Product Specifications: Methods of Establishment

